PT  - JOURNAL ARTICLE
AU  - Hani A. Nabi
AU  - José M. Zubeldia
TI  - Clinical Applications of <sup>18</sup>F-FDG in Oncology
DP  - 2002 Mar 01
TA  - Journal of Nuclear Medicine Technology
PG  - 3--9
VI  - 30
IP  - 1
4099  - http://tech.snmjournals.org/content/30/1/3.short
4100  - http://tech.snmjournals.org/content/30/1/3.full
SO  - J. Nucl. Med. Technol.2002 Mar 01; 30
AB  - PET has emerged as a powerful diagnostic tool for the evaluation of cancer patients. Currently, most of these studies are performed with the glucose analog 18F-FDG, which has been shown to accumulate avidly in most tumors. 18F-FDG PET is now routinely used in the diagnosis, staging, and posttherapy evaluation of oncologic patients. After reading this paper, the reader should understand the physiologic basis of using 18F-FDG in patients with different tumors, describe the role of this radiopharmaceutical in the management of oncologic patients, and identify those malignancies for which 18F-FDG has proved to be effective in diagnosis and follow-up.